News Releases

Read all the latest news from Bristol Myers Squibb the Netherlands here.

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis >
Bristol Myers Squibb today announced that the European Commission has approved Sotyktu (deucravacitinib), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy, representing a new way of treating this chronic immune-mediated disease.


Bristol Myers Squibb celebrates highest point in first European cell therapy production facility construction at Leiden Bio Science Park >
The construction of the CAR T cell therapy production centre of Bristol Myers Squibb in the Leiden Bio Science Park (LBSP) is nearing completion. Today the highest point was reached which traditionally means a topping-off ceremony. 

Contact details for media

Didn't find the information you were looking for or do you have further questions? Please contact us directly. We will be happy to help you out!

 

Ronald Jager

Senior Manager Corporate Affairs

 

Phone number: +31 30 300 22 22

 

E-mail: info.nl@bms.com

 

For all other questions

If you are not a member of the press and have a non-media related question then find the right contact information here. This will enable us to help you faster!